Albireo Launches Critical Alarm Management Service for Mission Critical Buildings that Require Uptime and ReliabilityBusiness Wire • 05/06/24
Albireo Energy Sees Buildings in a Different Way as it Unveils New Brand IdentityBusiness Wire • 12/14/23
Is Albireo Pharma (ALBO) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 03/01/23
Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023GlobeNewsWire • 02/22/23
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille SyndromeGlobeNewsWire • 02/14/23
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing InvestigationsPRNewsWire • 01/31/23
ALERT: The M&A Class Action Firm Announces the Investigation of Albireo Pharma, Inc. - ALBOPRNewsWire • 01/10/23
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Albireo Pharma, Inc. BuyoutNewsfile Corp • 01/09/23
Shareholder Alert: Ademi LLP investigates whether Albireo Pharma, Inc. has obtained a Fair Price in its transaction with IpsenPRNewsWire • 01/09/23
ALBO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Albireo Pharma, Inc. Is Fair to ShareholdersBusiness Wire • 01/09/23
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver DiseasesBusiness Wire • 01/09/23
Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D.GlobeNewsWire • 12/06/22
Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2GlobeNewsWire • 11/30/22